References of "Bolle, Stéphanie"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailInnovations technologiques en radiothérapie-oncologie
Coucke, Philippe ULg; Louis, Céline ULg; Bolle, Stéphanie

in Revue Médicale de Liège (2007), 62 (5-6)

InnovatIve technologIes In radIatIon oncology SUMMARY : At present, radiation oncology is again flourishing thanks to the development of highly accurate techniques as intensity modulated radiation therapy ... [more ▼]

InnovatIve technologIes In radIatIon oncology SUMMARY : At present, radiation oncology is again flourishing thanks to the development of highly accurate techniques as intensity modulated radiation therapy, stereotactic radiation therapy and hadrontherapy. These therapeutic modalities are made possible by the advent of image guided radiation therapy and respiratory gating that allows a better patient repositioning during the irradiation and between fractions. Nowadays, thanks to these recent technological advances, one can more easily conceive dose escalation, hypofractionation and combined treatment of radiation with sensitizing drugs and this together with a better protection of normal tissue aiming at, simultaneously, improved tumour control and better quality of life. This article describes these innovative technologies that, when integrated to other anti-tumoral therapeutic modalities, seem to be very promising. Keywords : - [less ▲]

Detailed reference viewed: 71 (5 ULg)
Full Text
Peer Reviewed
See detailClinical added-value of 18FDG PET in neuroendocrine-Merkel cell carcinoma
Belhocine, Tarik; Pierard, Gérald ULg; Frühling, Janos et al

in Oncology Reports (2006), 16(2), 347-352

Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of (18)FDG PET in the management of MCC. Eleven patients with MCC ... [more ▼]

Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of (18)FDG PET in the management of MCC. Eleven patients with MCC were examined by (18)FDG PET and PET-CT for staging purpose (n=4) or for detection of recurrence (n=7). Qualitative and quantitative interpretation of PET studies was performed routinely. (18)FDG PET observations were compared to clinical and radiological findings. In 6 patients, PET findings were also compared to histology. In 7 patients, the (18)FDG tumor uptake was compared to the MCC proliferative activity expressed by the Ki-67 index. (18)FDG PET was contributive in 10/11 MCC patients. In 7 patients, (18)FDG PET detected focal lesions or a disseminated stage of the disease including dermal, nodal and visceral metastases. In 3 patients, a normal (18)FDG PET confirmed complete remission of disease. Most MCC patients exhibited highly (18)FDG-avid sites suggestive of increased glucose metabolism. This imaging pattern was related to a high proliferative activity (Ki-67 index > 50%). In 1 patient with a weakly proliferative nodal MCC (Ki-67 < 10%), a false negative result was yielded by metabolic imaging. In 4/11 patients, (18)FDG PET revealed an unsuspected second neoplasm in addition to MCC. It is concluded that whole-body (18)FDG PET may be useful in the management of MCC patients. However, a normal (18)FDG PET aspect cannot rule out MCC with low proliferative activity. [less ▲]

Detailed reference viewed: 40 (5 ULg)
Full Text
Peer Reviewed
See detailClinical added-value of 18FDG PET in neuroendocrine-merkel cell carcinoma.
Belhocine, Tarik; Pierard, Gérald ULg; Frühling, Janos et al

in Oncology Reports (2006), 16(2), 347-52

Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of 18FDG PET in the management of MCC. Eleven patients with MCC ... [more ▼]

Merkel cell carcinoma (MCC) is a rare and highly malignant skin cancer with neuroendocrine differentiation. We studied the potential value of 18FDG PET in the management of MCC. Eleven patients with MCC were examined by 18FDG PET and PET-CT for staging purpose (n=4) or for detection of recurrence (n=7). Qualitative and quantitative interpretation of PET studies was performed routinely. 18FDG PET observations were compared to clinical and radiological findings. In 6 patients, PET findings were also compared to histology. In 7 patients, the 18FDG tumor uptake was compared to the MCC proliferative activity expressed by the Ki-67 index. 18FDG PET was contributive in 10/11 MCC patients. In 7 patients, 18FDG PET detected focal lesions or a disseminated stage of the disease including dermal, nodal and visceral metastases. In 3 patients, a normal 18FDG PET confirmed complete remission of disease. Most MCC patients exhibited highly 18FDG-avid sites suggestive of increased glucose metabolism. This imaging pattern was related to a high proliferative activity (Ki-67 index >50%). In 1 patient with a weakly proliferative nodal MCC (Ki-67<10%), a false negative result was yielded by metabolic imaging. In 4/11 patients, 18FDG PET revealed an unsuspected second neoplasm in addition to MCC. It is concluded that whole-body 18FDG PET may be useful in the management of MCC patients. However, a normal 18FDG PET aspect cannot rule out MCC with low proliferative activity. [less ▲]

Detailed reference viewed: 28 (3 ULg)